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Abstract: The bovine pancreatic trypsin inhibitor (BPTI)-Kunitz-type protein ShPI-1 (UniProt: P31713)
is the major protease inhibitor from the sea anemone Stichodactyla helianthus. This molecule is used in
biotechnology and has biomedical potential related to its anti-parasitic effect. A pseudo wild-type
variant, rShPI-1A, with additional residues at the N- and C-terminal, has a similar three-dimensional
structure and comparable trypsin inhibition strength. Further insights into the structure-function
relationship of rShPI-1A are required in order to obtain a better understanding of the mechanism
of action of this sea anemone peptide. Using enzyme kinetics, we now investigated its activity
against other serine proteases. Considering previous reports of bifunctional Kunitz-type proteins
from anemones, we also studied the effect of rShPI-1A on voltage-gated potassium (Kv) channels.
rShPI-1A binds Kv1.1, Kv1.2, and Kv1.6 channels with IC50 values in the nM range. Hence, ShPI-1
is the first member of the sea anemone type 2 potassium channel toxins family with tight-binding
potency against several proteases and different Kv1 channels. In depth sequence analysis and
structural comparison of ShPI-1 with similar protease inhibitors and Kv channel toxins showed
apparent non-sequence conservation for known key residues. However, we detected two subtle
patterns of coordinated amino acid substitutions flanking the conserved cysteine residues at the
N- and C-terminal ends.
Keywords: protease inhibitor; Kv channel inhibitor; sea anemone; toxin; Kunitz-type protein
1. Introduction
Cnidaria is an ancient clade of animals whose venom arsenal comprises biologically-active
compounds, such as proteases inhibitors and toxins, acting on ion channels, such as the transient
receptor potential family member vanilloid 1 (TRPV1) and voltage-gated sodium and potassium
channels [1–4]. Some toxin family types found in sea anemones have been previously identified in
other venomous organisms. The most striking examples are peptides from the Kunitz-type family,
also found in cone snails, insects, scorpions, spiders, reptiles and ticks. Most studies of Cnidarian
BPTI-Kunitz-type peptides are focused on their antiproteolytic effect [5,6]; however, their toxic effect
has been poorly investigated compared to similar proteins from other venomous animals.
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ShPI-1 (UniProt ID: P31713) is a well-known protease inhibitor isolated from the Caribbean Sea
anemone Stichodactyla helianthus, containing 55 amino acids cross-linked by three disulfide bridges.
This inhibitor has a broad specificity toward several serine proteases, i.e., trypsin, chymotrypsin,
human neutrophil elastase, kallikrein and plasmin, and can bind aspartic and cysteine proteases, such
as pepsin and papain, respectively [7]. A variant of ShPI-1 (rShPI-1A) containing the N-terminal
tag EAEA has been obtained to favor expression in the yeast Pichia pastoris [8]. This variant also
contains two C-terminal residues (LG) that remained as part of the cloning procedure. Despite these
differences, the X-ray structure of rShPI-1A is highly similar to the NMR structure of the molecule
purified from the natural source, thus demonstrating that the additional residues do not affect the
native fold [9]. Preliminary functional studies also revealed that these tags do not affect the specificity
and strength of trypsin inhibition [8]. Hence, the pseudo wild-type inhibitor rShPI-1A may be used
for structure-function relationship studies of ShPI-1, as well as for developing its already reported
biotechnological and biomedical applications [8,10,11].
ShPI-1 shares structural homology with both the very potent Kunitz-type protease inhibitor
BPTI and snake dendrotoxins (DTXs), which are powerful blockers of voltage-gated potassium
channels (KV) [12,13]. Five similar proteins from sea anemones have been shown to possess a dual
function, since they inhibit serine proteases and KV channels. Kalicludines (AsKC1-AsKC3) from
Anemonia sulcata are the first bifunctional BPTI-Kunitz-type proteins isolated from sea anemones [14].
Similar activities were later reported for SHTX-III from Stichodactyla haddoni and APEKTx1 from
Anthopleura elegantissima [15,16]. In general, little is known about the Kv channel subtype selectivity of
these type 2 toxins. A broad screening of different ion channels reported for the first time for APEKTx1
revealed a potent activity against KV1.1 with IC50 values in the lower nanomolar range and pointed out
an impressive selectivity for these channels over the other isoforms tested [16]. Such high molecular
specificity and potency has long made venoms a promising source of drug candidates. Moreover, these
molecules are valuable tools to study the structure and function of potassium channels and also to be
used for drug development.
S. helianthus, which lives on Caribbean reefs and uses its soft green tentacles to stun shrimp
with a cocktail of toxins, is the natural source of ShK, a type 1 potassium channel toxin that targets
KV1.1, KV1.3, KV1.6, KV3.2 and KCa3.1 channels [17]. New analogs of this molecule with improved
selectivity and pharmaceutical potentialities have been obtained, being perhaps the most compelling
venom-derived drug in development [18,19]. However, up to date, only two ion channel toxins, Shk
and the type 2 sodium channel toxin Sh1 [20], have been described in S. helianthus.
Here, together with a deeper functional characterization of the antiproteolytic activity of rShPI-1A,
we demonstrated that this molecule is a very potent voltage-gated potassium channel blocker, able
to bind KV1.1, KV1.2 and KV1.6 channels. Of note, ShPI-1 may be a new member of the type 2
potassium channel toxins family from sea anemones. Sequence and structural comparison of ShPI-1
and other Kv channel toxins revealed two subtle patterns of coordinated amino acid substitutions
[Xa´2Xa´1CysIXa+1Xa+2Xa+3] around the first cysteine residue (CysI) and [CysVXb+1Xb+2Xb+3CysVI]
that contain the CysV and CysVI residues toward the C-terminal of Kv blocking toxins sharing a
BPTI-Kunitz fold. Both patterns contain key residues for inhibition of potassium channels and are
close in space to each other, constituting a contact surface.
2. Results and Discussion
2.1. rShPI-1 Specificity and Dissociation Constants against Serine Proteases
The pseudo wild-type inhibitor rShPI-1A has been previously characterized by our group, but
mainly in terms of specificity and Ki values against trypsin [8]. Now, we extended the functional
characterization of this recombinant molecule by determining its specificity and Ki values against other
serine proteases previously tested with the natural inhibitor [7], besides factor Xa that has not been
formerly evaluated.
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As observed in Figure 1, rShPI-1A affected the enzymatic activities of trypsin-like enzymes,
i.e., pancreatic trypsin, plasmin and kallikrein. It also inhibited the activity of chymotrypsin and
human neutrophil elastase (HNE). Binding to the latter is in contrast with the absence of activity
against pancreatic elastase (Table 1), a behavior also detected in the natural molecule [7]. The concave
inhibition curves obtained under experimental conditions of [Eo]/Ki = 1–10 indicated that rShPI-1A is
a reversible inhibitor of pancreatic trypsin, as previously described [8], as well as of chymotrypsin,
HNE, plasmin and kallikrein. This behavior allowed determining the apparent Ki values (Figure 1).
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Figure 1. Protease inhibition curves using rShPI‐1A. Fixed concentrations of each enzyme were mixed with 
increasing  concentrations of  rShPI‐1A  (displayed  in nM). Each  enzymatic activity was determined after 
adding  the corresponding substrate  (see Materials and Methods  for experimental details). The  fractional 
enzymatic activities (vi/v0) were calculated after measuring the  initial reaction rates with (vi) and without 
inhibitor  (v0). Each  connecting  line  represents  the best  fits  to  the quadratic Morrison  equation  for  tight 
binding  inhibitors  described  in  [21].  Apparent  Ki  values  (Kiapp)  were  calculated  by  adjusting  the 
experimental points to that equation and are shown here as the mean ± SE (n = 3). 
Table 1. Specificity and Ki values of rShPI‐1A against serine proteases. 
Enzyme  I0/E0 Residual Activity (%) Ki Values (nM) 
Bovine pancreatic trypsin  0.2  63  (2.7 ± 0.3) 
Human plasmin  0.3  64  (4.4 ± 0.2) 
Porcine pancreatic kallikrein  0.6  63  (14.6 ± 2.00) 
Human factor Xa  a  100  N.i b 
Human α‐thrombin  a  100  N.i b 
Porcine pancreatic chymotrypsin  0.9  52  (14.8 ± 1.5) 
Human neutrophil elastase  0.6  66  (23.5 ± 2.0) 
Porcine pancreatic elastase  1–170  100  N.i b 
B. licheniformis subtilisin  1–240  100  N.i b 
Figure 1. Protease inhibition curves using rShPI-1A. Fixed concentrations of each enzyme were mixed
with increasing concentrations of rShPI-1A (displayed in nM). Each enzymatic activity was determined
after adding the corresponding substrate (see Materials and Methods for experimental details).
The fractional enzymatic activities (vi/v0) were calculated after measuring the initial reaction rates it
(vi) and without inhibitor (v0). Each connecting line represents the best fits to the quadratic Morrison
equation for tight binding inhibitors describ d in [21]. Apparent Ki values (Kiapp) were calculated by
adjusting the experimental points to that equation and are shown here as the mean ˘ SE (n = 3).
able 1. Specificity and i values of rShPI-1 against serine proteases.
Enzyme I0/E0 Residual Activity (%) Ki Values (nM)
Bovine pancreatic trypsin .2 63 (2.7 ˘ 0.3)
Human plasmin 0.3 64 (4.4 ˘ 0.2)
Porcine pancreatic kallikrein 0.6 63 (14.6 ˘ 2.00)
Human factor Xa a 100 N.i b
Human α-thrombin a 100 N.i b
Porcine pancreatic chymotrypsin 0.9 52 (14.8 ˘ 1.5)
Human neutrophil elastase 0.6 66 (23.5 ˘ 2.0)
Porcine pancreatic elastase 1–170 100 N.i b
B. licheniformis subtilisin 1–240 100 N.i b
a Enzyme amount was provided in enzymatic units (see Materials and Methods), and therefore, molar
concentrations were unavailable. b N.i means that no inhibition was detected, even increasing the ratios
of inhibitor vs. enzyme molar concentration (I0/E0) and the incubation times up to 30 min.
Real Ki values (Table 1) were then calculated considering the substrate concentration and indicated
that rShPI-1A is a tight-binding inhibitor (Ki ď 10´7 M [22,23]) of the five enzymes. Preincubation of
rShPI-1A with these serine proteases over varying periods of time did not affect its inhibitory capacity,
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suggesting that the maximal inhibitory capacity is reached within the first minute of incubation.
Moreover, in all cases, the fractional enzymatic activity (vi/v0, meaning the ratio between the initial
reaction rates with (vi) and without inhibitor (v0)) increased when substrate concentration was
increased. This demonstrates that the substrates induce enzyme-inhibitor complex dissociation,
thus corroborating the reversibility.
The interaction of ShPI-1 with its targeted proteases proceeds through the canonical mechanism
involving mainly the reactive P1 site of the primary binding loop [24]. Moreover, the basic residue
Lys13 at the P1 site is the main determinant for tight binding inhibition of trypsin-like enzymes [24,25].
The lower inhibition strength against kallikrein, compared to trypsin and plasmin, was expected
since the kallikrein S1 pocket accommodates Arg over Lys residues at the P1 site better [26]. This is
related to the substitution of Ser190, found in trypsin and plasmin, by Ala. Consequently, the S1
pocket of kallikrein lacks a hydrogen-bond partner for P1 Lys, which does not bind as tightly as Arg
at the inhibitor’s P1 site [27]. A similar, but even more marked preference for Arg is found in other
trypsin-like proteases from the coagulation pathway, e.g., α-thrombin and factor Xa, since their S1
pockets, also having Ser190, are slightly more hydrophobic and larger. This is consistent with the lack
of activity of rShPI-1A against these two enzymes, observed even using a high [I0]/[E0] ratio and
increasing the incubation times up to 30 min (Table 1).
The inhibition strength against serine proteases with other specificities, i.e., HNE and
chymotrypsin, was also lower (Ki 10´8 M) compared to trypsin. According to X-ray crystallography,
the interaction with chymotrypsin (PDB ID: 3T62) proceeds through a different conformation
(named up-conformation) of the P1 site at the entrance of the enzyme S1 pocket, as previously
reported for similar inhibitors [28]. The mode of accommodation in the catalytic pocket of HNE is still
unknown, but molecular modeling studies have suggested that polar desolvation and the presence of
Asp226 in HNE could favor the interaction with the basic P1 residue. These interactions cannot be
established by Thr226 of PPE, which precludes the insertion of K13 side-chain into the S1 subsite of
this enzyme [29], thus explaining the absence of activity against this enzyme.
2.2. Activity toward Kv Channels: Electrophysiological Recordings
rShPI-1A was subjected to a screening on eight cloned voltage-gated potassium channels
(rKv1.1, rKv1.2, hKv1.3, rKv1.4, rKv1.5, rKv1.6, Shaker IR, hKv2.1) (Figure 2). Although only lower
concentrations of peptide were tested, 50 nM of rShPI-1A was able to block Kv1.1, Kv1.2 and Kv1.6
channels. The same concentration had no effect on other Kv channel isoforms from the Shaker (Kv1.3,
Kv1.4-Kv1.6 and Shaker IR) or Shab (Kv2.1) families. Concentration response curves were constructed
to determine the values at which half of the channels were blocked by rShPI-1A. The IC50 values
obtained are shown in Table 2. Kv1.2 channels were used to further investigate the characteristics of
inhibition. The inhibition of Kv1.2 channels induced by the toxin was not voltage dependent, as in
the range of test potentials from ´30 mV to +30 mV, no difference in the degree of blockade could
be observed.
To investigate whether the observed current inhibition is attributed to obstruction of the pore
rather than to altered channel gating upon toxin binding, the IV curves were constructed (Figure 3).
The IV curves in the control and in the presence of 50 nM peptide were characterized by V1/2 values of
14 ˘ 2 and 15 ˘ 2 mV (n ě 3), respectively. It can be concluded that no significant shift in the midpoint
of activation occurred (p < 0.05). Altogether, these experiments imply that current inhibition upon
rShPI-1A binding does not result from changes in the voltage dependence of channel gating. Upon
washout the current recovered quickly and completely (data not shown), suggesting that inhibition of
Kv1.2 channels occurred rapidly and that its binding was reversible.
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Figure 2. Activity of rShPI-1A on ion channels expressed in X. laevis oocytes. Traces are representative
of at least three independent experiments (n ě 3). The dotted line indicates the zero current level.
The asterisk (*) distinguishes the steady-state current after application of 50 nM peptide.
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Figure 3. Characterization of rShPI-1A activity on channel gating. Left panel: current-voltage
relationship. Closed symbols are the control condition; open symbols are after application of 50 nM
peptide. Right panel: concentration-response curve on Kv1.1 and Kv1.2 channels obtained by plotting
the percentage of blocked current as a function of increasing toxin concentrations. All data represent at
least three independent experiments (n ě 3) and are presented as the mean ˘ standard error.
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According to these results, rShPI-1A, a recombinant wild-type variant structurally similar to the
canonical serine protease inhibitor ShPI-1 from the sea anemone S. helianthus, is a potent Kv channel
inhibitor. This behavior indicates that ShPI-1 is a new member of the type 2 sea anemone toxins family.
Compared to the other five reported members of this family known to target also a serine protease,
i.e., trypsin (Table 2), rShPI-1A is unique in its ability to strongly inhibit a broader spectrum of serine
proteases, together with a potent activity against more than one Kv channel, i.e., Kv1.1, Kv1.2 and
Kv1.6 channels.
Table 2. Sea anemone proteins with bifunctional activity, toward serine proteases and Kv channels.
Organism Inhibitor UniProt AntiproteaseKi (nM) Kv Inhibition
a (IC50) Reference
Stichodactyla
helianthus ShPI-1
P31713 See Table 1
117 ˘ 15 nM (Kv1.1) this study
9 ˘ 2 nM (Kv1.2) + (Kv 1.6)
Anemonia
sulcata
AsKC1 Q9TWG0 Tr: <30 2.8 µM/Kv1.2
[14]AsKC2 Q9TWF9 Tr: <30 1.1 µM/Kv1.2
AsKC3 Q9TWF8 Tr: <30 1.3 µM/Kv1.2
Anthopleura
elegantissima APEKTx1 P86862 Tr: 120 0.9 nM/Kv1.1 [16]
Stichodactyla
haddoni
SHTX-3 B1B5l8
Tr: 203
IU/mg
0.65 mM b [15]
(270 nM) c
Tr: Trypsin. Empty spaces mean activities not tested or referred to. a Specificity towards different K+ channel
subtypes is included if available; b crab-paralyzing activity determined using synaptosomal binding assay;
c competitive binding to I125-αDTX.
The main strategy of venomous animals in either defense or predation situations is prey
immobilization through a mix of compounds exhibiting a variety of bioactivities and functions,
such as protease inhibitors, epidermal growth factor (EGF)-like peptides (i.e., gigantoxin in S. gigantea),
phospholipases A2, cytolysins and ion channel modulators. Peptide fingerprint data of a neurotoxic
pool from S. helianthus revealed a total of 113 peptide components ranging from 1275.9 Da–8615.5
Da [30]. Nearly 20 of these peptides are found in six lethal fractions of the anemone that induced crab
paralysis, including spastic and tetanic reactions, with different degrees of intensity within seconds
to several minutes. Despite this complexity, only two Kunitz-type protease inhibitors ShPI-I and
ShPI-II [7,31] and four toxic polypeptides are reported in S. helianthus: two pore-forming cytolysins,
sticholysins I and II [32]; and two ion channel blockers, Sh1 and ShK [17,20]. The cytolytic effects
of the two pore-forming proteins include red blood cell hemolysis, platelet aggregation and lysis
and cytotoxic and cytostatic effects on fibroblasts [33]. Lethality in mammals has been ascribed to
severe vasospasm of coronary vessels, cardiac arrhythmia and inotropic effects. The toxin ShI, which
specifically binds Nav channels, is selectively toxic to crustaceans [20,30].
The dual effect toward protease and the ion channel detected here for ShPI-1 and reported in
another five proteins from sea anemones (Table 3) has been assumed as an economic manner to save
energy and an advantage for these organisms from both an offensive and defensive point of view [16].
According to [14], these molecules are survivors of a remote past in which evolution gave rise to
more than one function in the same scaffold. Thus, the number of proteins acting on ion channels is
rationalized, and the efficiency is increased, since the same polypeptide ensures: (i) the paralysis of
the prey, though a toxic activity; and (ii) the protection against degradation of peptidic toxins injected
into the prey, through the inhibition activity against proteases. Since ShPI-1 is able to inhibit a broad
spectrum of serine proteases, including plasmin and kallikrein, it could ensure not only the protection
of S. helianthus toxins, but also an additional effect on the prey’s enzymes.
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Table 3. BPTI-Kunitz-type Kv channel toxins from non-anemones animal venoms.
Taxon Toxin UniProt PDB Target (IC50, nM) Key Residues * Reference
snakes
α-DTX P00980 1DTX
Kv1.1 (1.1–150)
R3, R4, K5, L6, I8, L9 [13]Kv1.2 (0.4)
Kv 1.6 (9.0)
DTX-K P00981 1DTK Kv1.1 (2.5) (0.03) K25, Y26, K28, P30, R32, P35,K37-K39, K46-K50, R74, R75 [34,35]
DTX-I P00979
1DEM
1DEN
Kv1.1 (3.1)
K5, L9, K29 [13]Kv1.2 (0.13)
Kv1.6; Kv1.3; Kv1.5
(weaker)
scorpion
Hg1 P0C8WT - Kv1.3 (6.2) C-terminal (K77, R78, F82, K84) [36]
LmKTT-1a P0DJ46 2M01 Kv1.3 (>1000) - [36]
LmKTT-1b P0DJ45 - Kv1.3 (>1000) - [36]
LmKTT-1c P0DJ48 - Kv1.3 (>1000) - [36]
BmKTT-1 P0DJ49 - Kv1.3 (129.7) - [36]
BmKTT-2 P0DJ50 - Kv1.3 (371.3) - [36]
BmKTT-3 P9DJ47 - Kv1.3 (>1000) - [36]
spider HWTX-XI P68425 2JOT
Kv1.1 (2.6 mM)
R38-L39 [37]Kv1.2; 1.3 (weaker)
Conus
mollusk Conk-S1
P0C1X2
2CA7 Kv1 (60) No dyad needed; K47, R60 [38–40]1Y62 Kv1.7 (439)
* Based on site-directed mutagenesis studies and using the numbering system at UniProt. Residues referred in
the literature as “functional dyads” are underlined. The symbol (-) means unavailable data.
2.3. Sequence and Structural Comparison of ShPI-1 and Other Kv Channel Toxins
In a first attempt to explain Kv channel inhibition activities of ShPI-1, we carried out a sequence
comparison between the five BPTI-Kunitz-type proteins from sea anemones shown in Table 3 and
structurally-similar Kv channel blocking toxins from the snake Dendroaspis polylepis. The preliminary
sequence comparison showed that most key residues reported for Kv channel inhibition in DTXs are
not conserved among currently-known sea anemone toxins (Figure 4).
For example, the dyad Lys5/Leu9, crucial for the interaction of α-DTX with Kv channels [12,41],
is only fully conserved in the kalicludines AsKC1 and AsKC2 [14]. This observation indicated that
the functional dyad found in α-DTX and DTX-I is not needed in ShPI-1 or that this function can be
fulfilled by other residues, as previously suggested for similar sea anemone toxins (i.e., SHTXIII and
APEKTx1, [16]).
Next, we included similar toxins from other venomous animals, some of them with known
residues involved in Kv channel inhibition or with 3D structures already described. Information about
all toxins used in the sequence comparison is shown in Table 3. As shown in Figure 4, the functional
dyads or other key residues in DTXs and similar toxins from other venomous animals are located
mainly toward the N- and C-terminal regions of the proteins, in particular around CysI and
CysV-CysVI, respectively.
A number of known key residues is localized outside these two regions, i.e., over a β-sheet
surface in the vicinity of the reactive loop needed for serine protease inhibition (Figures 4 and 5).
However, these data should be considered with caution. For example, Lys19 in DTX-I and α-DTX has
the UniProt annotation “not important for inhibition of potassium channels”, while the equivalent
Lys39 in DTX-K contains the annotation “KÑ A: Slight decrease in binding affinity for Kv. Important
decrease in binding affinity for Kv, when associated with K48A”. In addition, the identification of
key residues might be influenced by the subtype of the potassium channels used in the experiments,
e.g., most of the α-DTX-susceptible Kv channels in bovine brain contain different subtypes and are
composed of heterooligomeric mixtures: Kv1.2 (~80%) or Kv1.1 (~50%) [42].
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Despite an apparent non-sequence conservation in key positions; we observed two subtle patterns
of coordinated amino acid substitutions in different regions of Kv blocking toxins sharing a BPTI-Kunitz
fold, i.e., [Xa´2Xa´1CysIXa+1Xa+2Xa+3] flanking the conserved cysteine (CysI) at the N-terminal and
[CysVXb+1Xb+2Xb+3CysVI] toward the C-terminal. Both patterns contain key residues for inhibition of
potassium channels (Figure 4) and are close in space to each other, constituting a contact surface, as will
be discussed later. The amino acid residues at positions Xa´1, CysI, Xa+2, CysV, Xb+3, CysVI (shown in
gray in Figure 4) are not exposed or only partially exposed in the BPTI-Kunitz fold. These residues
establish a network of backbone-backbone and backbone-side chain interactions due to the conserved
disulfide bridge CysI-CysVI (more details in Supplementary File 1).
Therefore, we focused the analysis on fully-solvent-exposed positions (accessible surface area
(ASA) > 50%) to predict amino acids important for Kv-blocking in sea anemone type II toxins. As shown
in Figure 4, the fully-exposed positions Xa´2, Xa+1, Xa+3, Xb+1 and Xb+2 contain at least one important
residue in snake dendrotoxins and toxins from other venomous animals. The position Xa´2 contains
the key residues Lys5 in α-DTX and DTX-I and Lys25 in DTX-K; Xa+1 the Ile8 in α-DTX, Lys28 in
DTX-K and Arg38 in HWTX-XI; Xa+3 the Pro30 in DTX-K; Xb+1 the Arg74 in DTX-K; and Xb+2 the
Arg75 in DTX-K and Lys77 in Hg-1.
Replacement of Lys25, found in DTX-K, by an Asp residue (Xa´2) in HWTX-XI, together with
the absence of Trp47 and Lys48 in the latter, is proposed to explain the lower activity of the spider
toxin. In DTX-K, however, the presence of Trp47 is suggested to provide a more effective hydrophobic
binding surface to the Kv1.1 turret [37]. The toxins αDTX, DTX-I and DTX-K, from the dendrotoxin
subfamily, possess similar IC50 values for Kv1.1 (Table 4). According to the alignment in Figure 4,
positions Xa´2, Xb+1 and Xb+2 accommodate a positive charge (Arg, Lys), but positions Xa+1 and
Xa+3 differ between these protein isoforms or paralogous sequences. DTX-I and α-DTX contain a
hydrophobic residue (Ile) in Xa+1 and a positive charge (His) in Xa+3. Then, a single substitution at
one of these positions should be “compensated” by a second substitution to preserve the specificity
in the interaction. In agreement with this criterion, DTX-K shows two coordinated substitutions in a
“compensated” manner: Ile is replaced by Lys in Xa+1, and His is replaced by Pro in Xa+3. In this way,
the balance of physical-chemical properties from residues close in space is preserved. However, specific
cases where substitutions are “not compensated” should indicate that the toxin modifies its interaction
specificity in comparison to protein isoforms or paralogous sequences.
Other possibilities of coordinated substitutions are observed in different subfamilies (Figure 4).
Toxins from other venomous animals show conserved hydrophobic residues (Pro) at Xa+3 and a
positive charge (Arg, Lys) at Xb+2. The other three fully-exposed positions (Xa´2, Xa+1, Xb+1) in this
subfamily vary in a “non-compensated” manner, which indicates that protein isoforms or paralogous
sequences modify their interaction specificities. Nevertheless, some of these toxins might share the
same specificity (i.e., LmKTT-1a and BmKTT-1 and also LmKTT-1b and LmKTT-1c) because they
preserve the distribution of hydrophobic residues (green), charged (blue, red) and polar uncharged
(magenta) at equivalent positions (Figure 4).
Concerning the sea anemone type II toxins subfamily, AsKC1 and AsKC2 should have the same
specificity, but different from AsKC3 and the other members. In addition, the pattern of hydrophobic
residues, charged and polar uncharged is somehow similar to the pattern observed in toxins from
other venomous animals (Figure 4).
It is worth mentioning that the patterns of coordinated amino acid substitutions here proposed
for BPTI-Kunitz-type toxins could be masked due to: (i) a few number of reported proteins with
bifunctional activity; and (ii) possibly other as yet undescribed protein isoforms or paralogous
sequences in these organisms having a different pattern of coordinated amino acids substitutions.
Nevertheless, the two patterns here proposed are in agreement with the widely-accepted hypothesis
stating that functional residues in a protein family sharing the same fold and related functions tend to
be conserved through evolution at equivalent positions [43].
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On the other hand, we investigated the spatial disposition of key residues (e.g., reported dyads)
among toxins having a BPTI-Kunitz fold or not, through structural superposition of these proteins
using the PDBeFold method [44] (Figure 5). We observed that the C-terminal α-helix in proteins
sharing the BPTI-Kunitz fold is the unique secondary structure element well superposed with similar
helical structures found in toxins having a different fold, but displaying also activity toward Kv
channels. Moreover, the proposed pattern CysVXb+1Xb+2Xb+3CysVI is positioned in the C-terminal
α-helix. Note as well that the structurally-superposed α-helices also contain the reported dyads
Lys25-Tyr26 in BgK and Lys22-Tyr23 in ShK, both ShK-type toxins sharing an all-alpha fold (Figure 5).
A combined analysis of the [CysVXb+1Xb+2Xb+3CysVI] pattern with the structure-based sequence
alignment of Kv-channel blocking toxins (Figure 5) allows us to propose that the Kv channel inhibition
activity here detected in ShPI-1 involves residues around positions Xb+1-Xb+2 in the C-terminal α-helix.
We are aware that other residues inside or nearby the [Xa´2Xa´1CysIXa+1Xa+2Xa+3] pattern could
contribute to the interaction with the Kv channels. At the same time, this pattern creates a differential
distribution of polar and non-polar groups on a common interacting surface between protein isoforms
or paralogous sequences and Kv channels (Figure 6).
1 
 
 
Figure 6. Surface electrostatic potential representation of toxins. The surface is colored according to the
electrostatic potential: negative regions (in red), positive regions (in blue) and neutral regions (in gray).
The orientation of the surface electrostatic potentials is the same as that in the ribbon representation
at the bottom right. The list of PDB codes for toxins is as follows: ShPI-1 (3M7Q); LmKTT-1a (2M01);
HWTX-XI (2JOT); Conk-S1 (1Y62); α-DTX (1DTX); DTX-K (1DTK); DTX-I (1DEM); BgK (1BGK); ShK
(4LFS); and ChTX (1BAH). We also provided a color intensity scale to better represent the electrostatic
potential. BPTI-Kunitz-type toxins are displayed in the first two lines. These figures were prepared
with the PyMOL Molecular Graphics System, Schrödinger, LLC.
Previous investigations of scorpion toxins indicate that the positive ammonium group of the lysine
residue in the dyad may mimic K+ ions entering the pore, occluding the ion pathway. A similar role
is associated with the functional lysine of the toxins from sea anemones [45]. It is also proposed
that the interaction with the channel occurs by the helix side of the toxin and that the β-sheet
charged surface is important for a second step following toxin binding [46]. For a recent review
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about computational studies of venom peptides targeting Kv channels, see Chen and Chung [47].
Altogether, these results hint at the functional importance of positively-charged residues in the
protein surface. In Figure 6, we present the surface electrostatic potential of the Kv channel-blocking
toxins here analyzed. As seen, the distribution of positively-charged residues differs between toxins.
However, a planar negatively-charged surface at the bottom is a common feature of the toxins having
the BPTI-Kunitz fold (first two lines in Figure 6). Both the N- and C-terminal helices contribute to
this negatively-charged surface. Interestingly, only ShPI-1, LmKKT-1a, HWTX-XI and DTX-K have a
remarkable positive charge in the reactive loop that is needed by Kunitz-type proteins for the inhibition
of serine proteases.
It should be noted, however, that besides the functional dyad, other toxin determinants are
required for a high affinity interaction between a toxin and its target [48]. Known examples of toxins
lacking a dyad, but still capable of blocking the Kv channel (or the other way around, toxins with a
dyad, but incapable of blocking) strongly suggest that the functional dyad on its own cannot represent
the minimal pharmacophore or prerequisite for Kv1 binding [49]. Thus, further structure-function
studies, such as site-directed mutagenesis experiments, may help to determine which amino acids are
the key residues for the Kv channel-inhibiting activity of ShPI-1.
3. Materials and Methods
3.1. Protein Production and Purification
The inhibitor rShPI-1A was expressed in a 1.5-L working volume fermenter (B.E. Marubishi,
Tokio, Japan) using the conditions previously established [8]. Secretion of the protein to the
medium was evaluated by SDS-PAGE [50] and the determination of inhibitory activity against bovine
pancreatic trypsin (EC 3.4.21.4) using the substrate N-benzoyl-arginine-p-nitroanilide (BAPNA) [51].
Protein purification was performed in a Streamline™ (GE Healthcare, Uppsala, Sweden) Direct HST-1
cation-exchange column according to [8]. The elution profile was monitored at 280 nm, and the
inhibitory activity against pancreatic trypsin was tested as described [51]. The protein concentration
was estimated by measuring the absorbance at 280 nm using the extinction coefficient (E280 1% = 5.2)
reported for natural ShPI-1 [7].
Table 4. Experimental conditions for serine protease inhibition assays.
Enzyme [E0]
1
(M or U)2
Substrate (Reference) [S0](mM) 2 Buffer
trypsin 2.2 10´7 Bz-Arg-pNa [51] 1.0 20 mM Tris-HCl; 150 mMNaCl; 20 mM CaCl2; pH 8.0
kallikrein 5.4 10´7 HD-Val-Leu-Arg-pNA [52] 0.5 50 mM Tris-HCl; 16 mMNaCl; pH 7.8
plasmin 2.4 10´8 HD-Val-Leu-Lys-pNA [53] 0.4 50 mM Tris-HCl; 110 mMNaCl; pH 7.4
factor Xa 0.1 U Bz-Ile-Glu-Gly-Arg-pNA [54] 0.4 50 mM Tris-HCl; 130 mMNaCl; 20 mM CaCl2; pH 8.3
thrombin 1.0 U HD-Phe-Pip-Arg-pNA [55] 0.4 50 mM Tris-HCl; 130 mMNaCl; 20 mM CaCl2; pH 8.3
chymotryp. 2.8 10´8 Suc-Ala-Ala-Pro-Phe-pNA [56] 1.0 50 mM Tris-HCl; pH 8.0
neutrophil
elastase 2 1.0 10
´7 MeOSuc-Ala-Ala-Pro-Val-pNA [57] 0.14 20 mM Tris-HCl; 500 mMNaCl; pH 8
pancreatic
elastase 3.3 10
´8 Suc-Ala-Ala-Ala-pNA [57] 0.7 30 mM Sodium Phosphate;50 mM NaCl; pH 7.0
subtilisin A 2.3 10´9 Suc-Ala-Ala-Pro-Phe-pNA [58] 0.12 100 mM Tris-HCl; 0.1%Triton X-100 ; pH 8.6
1 Abbreviations used: [E0], enzyme concentration; U, enzyme activity units; [S0], substrate concentration, around
1 KM in all enzymes; KM, Michaelis constant. 2 Concentrations in the assays. One unit of enzymatic activity was
defined as the amount of enzyme able to hydrolyze 1 µmol of substrate per min under the specified conditions.
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3.2. Protease Inhibition Studies
3.2.1. Inhibitory Specificity toward Serine Proteases
The specificity of rShPI-1A was evaluated against the following serine proteases: chymotrypsin
from bovine pancreas (EC 3.4.21.1); elastase (EC 3.24.21.36) and tissue kallikrein (3.4.21.35),
both from porcine pancreas; human neutrophil elastase (EC 3.4.21.37), plasmin (EC 3.24.21.7),
thrombin (EC 3.24.21.5), coagulation factor Xa (EC 3.24.21.6); and Bacillus licheniformis subtilisin A
(EC 3.4.21.62) (Table 4). All assays (n = 3) were performed in an Ultrospect 4000 spectrophotometer
(Pharmacia Biotech, Uppsala, Sweden), under initial velocity conditions. The substrate hydrolysis was
followed at 25 ˝C by recording the absorbance at 405 nm for 3 min with 15-s intervals.
The inhibitory activities were determined after incubating the inhibitor with the enzymes for
10–30 min at 25 ˝C and determining the residual enzymatic activities. One unit of inhibitory activity
was defined as the amount of protein needed to inhibit one unit of enzymatic activity, which was
defined as the amount of enzyme able to hydrolyze 1 µmol of substrate per min under the specified
conditions. The time needed to reach inhibition equilibrium was previously established for each
assay by preincubating rShPI-1A with the enzymes for 1, 5, 10 or 20 min before substrate addition.
Additionally, the effect of substrate concentration was determined using concentrations equivalent to
0.5 KM, 1 KM and 2 KM.
3.2.2. Determination of the Equilibrium Dissociation Constants (Ki)
The active concentration of trypsin was measured with a standard solution of p-nitrophenyl-p1-
guanidinium benzoate (9.4 µM) [59]. The inhibitor active concentration was evaluated by titration
with trypsin under conditions of [E0]/Ki ě 100 and assuming an equimolar enzyme:inhibitor complex.
The active inhibitor concentration was assessed at the equivalence point (where [Et] = [It]) in a plot
of residual enzymatic activity versus the inhibitor volume. Equilibrium dissociation constants were
determined by measuring the residual enzymatic activities (vi) after pre-incubation of enzymes with
increasing concentrations of inhibitor under conditions of [E0]/Ki = 10. Apparent Ki values (Kiapp) were
obtained by adjusting the experimental points to the equation described for tight binding inhibitors [21],
using non-linear fitting with GraFit v.3.01 (Erithacus Software Ltd, Horley, UK, 1997). Real Ki values
were calculated using the equation Ki = Kiapp/([S0]/(KM) + 1), considering the substrates concentration
[S0] and their reported KM values (Table 4).
3.3. Voltage-Gated Ion Channel Inhibition Experiments
3.3.1. Expression of Voltage-Gated Ion Channels in Xenopus laevis Oocytes
For the expression of the voltage-gated potassium channels (rKv1.1, rKv1.2, hKv1.3, rKv1.4,
rKv1.5, rKv1.6, Shaker IR, hKv2.1) in Xenopus oocytes, the linearized plasmids were transcribed using
the Ambion™ T7 or SP6 mMESSAGE-mMACHINE transcription kit (Thermofisher, Houston, TX,
USA). The harvesting of Stage V–VI oocytes from an anaesthetized female Xenopus laevis frog was
carried out as previously described [16]. Oocytes were injected with 50 nL of cRNA at a concentration
of 1 ng/nL using a micro-injector (Drummond Scientific, Broomall, PA, USA). The oocytes were
incubated in a solution containing: 96 mM NaCl; 2 mM KCl; 1.8 mM CaCl2; 2 mM MgCl2 and 5 mM
HEPES (pH 7.4), supplemented with 50 mg/L gentamycin sulfate.
3.3.2. Electrophysiological Recordings
Two-electrode voltage-clamp recordings were performed at room temperature (18–22 ˝C) using a
Gene Clamp 500 amplifier (Molecular Devices, Sunnyvale, CA, USA) controlled by a PClamp data
acquisition system (version 10, Axon Instruments, Molecular Devices, Sunnyvale, CA, USA, 2011).
Whole cell currents from oocytes were recorded 1–4 days after injection. The bath solution composition
was 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2 and 5 mM HEPES (pH 7.4). Voltage and
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current electrodes were filled with 3 M KCl. Resistances of both electrodes were kept between 0.7 and
1.5 MΩ. The elicited potassium currents were filtered at 0.5 kHz and sampled at 2 kHz using a four-pole
low-pass Bessel filter (Molecular Devices, Sunnyvale, CA, USA). Leak subtraction was performed
using a ´P/4 protocol. KV1.1–KV1.6 and Shaker currents were evoked by 250-ms depolarizations
to 0 mV followed by a 250-ms pulse to ´50 mV, from a holding potential of ´90 mV. For KV2.1,
currents were elicited by 500-ms pulses to +20 mV from a holding potential of ´90 mV. In order to
investigate the current–voltage relationship, current traces were evoked by 10-mV depolarization steps
from a holding potential of ´90 mV. To assess the concentration dependency of the toxin-induced
inhibitory effects, a concentration-response curve was constructed, in which the percentage of current
inhibition was plotted as a function of toxin concentration. Data were fitted to the Hill equation:
y = 100/[1 + (IC50/[toxin])h], were y is the amplitude of the toxin-induced effect, IC50 is the toxin
concentration at half-maximal efficacy, [toxin] is the toxin concentration and h is the Hill coefficient.
A comparison of two sample means was made using a paired Student’s t test (p < 0.05). All data
represent at least 3 independent experiments (n ě 3) and are presented as the mean ˘ standard error.
3.4. Computational Analyses
Sequences and three-dimensional (3D) structures of ShPI-1 and other toxins here analyzed were
retrieved from the UniProt/Swiss-Prot and the Protein Data Bank (PDB) databases respectively.
ClustalOmega [60] was used for multiple sequence alignment. Structural comparisons were performed
using PDBeFold [44]. The interatomic contacts and accessible surface area (ASA) relative to the residue
in a vacuum were calculated using WHAT IF [61].
Supplementary Materials: The following is available online at www.mdpi.com/2072-6651/8/4/110/s1: the
Supplementary File 1.
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Abbreviations
The following abbreviations are used in this manuscript:
3D three-dimensional
ASA accessible surface area
BAPNA N-benzoyl-arginine-p-nitroanilide or Bz-Arg-pNA
BPTI bovine pancreatic trypsin inhibitor
DTX dendrotoxin
Ki equilibrium dissociation constant
Kv voltage-gated potassium channel
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
ShPI-1 Stichodactyla helianthus protease inhibitor 1
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